nicotinic acid Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
nicotinic acid or nicotinoyl alcohol derivatives 2835 59-67-6

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • niacin potassium
  • niacin magnesium
  • nicotinic acid
  • vitamin b3 (niacin)
  • 3-pyridinecarboxylic acid
  • niaspan
  • niacin
  • niacor
  • Vitamin B3
A water-soluble vitamin of the B complex occurring in various animal and plant tissues. It is required by the body for the formation of coenzymes NAD and NADP. It has PELLAGRA-curative, vasodilating, and antilipemic properties.
  • Molecular weight: 123.11
  • Formula: C6H5NO2
  • CLOGP: 0.80
  • LIPINSKI: 0
  • HAC: 3
  • HDO: 1
  • TPSA: 50.19
  • ALOGS: -0.17
  • ROTB: 1

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
0.20 g O
0.20 g P
2 g O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 16.66 mg/mL Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 101.53 ┬ÁM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD

Approvals:

DateAgencyCompanyOrphan
July 24, 1957 FDA MEDPOINTE PHARM HLC

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Flushing 1133.61 37.66 232 817 11639 2345397
Drug hypersensitivity 771.65 37.66 222 827 46421 2310615
Pruritus 549.36 37.66 169 880 43171 2313865
Skin burning sensation 246.88 37.66 49 1000 1907 2355129
Erythema 216.51 37.66 74 975 25085 2331951
Feeling hot 156.83 37.66 43 1006 6885 2350151
Urticaria 150.09 37.66 56 993 24205 2332831
Rash 145.54 37.66 71 978 59487 2297549
Paraesthesia 143.98 37.66 53 996 22035 2335001
Burning sensation 99.13 37.66 31 1018 7797 2349239
Product residue present 93.45 37.66 20 1029 1116 2355920
Myalgia 85.38 37.66 37 1012 23296 2333740
Rhabdomyolysis 82.54 37.66 26 1023 6678 2350358
Dyspnoea 63.33 37.66 46 1003 78687 2278349
Nausea 61.04 37.66 52 997 112137 2244899
Swelling face 58.70 37.66 22 1027 9471 2347565
Dizziness 53.36 37.66 37 1012 58628 2298408
Blood glucose increased 53.19 37.66 22 1027 12268 2344768
Hot flush 53.08 37.66 19 1030 7180 2349856
Myopathy 51.17 37.66 13 1036 1530 2355506
Low density lipoprotein increased 48.63 37.66 12 1037 1254 2355782
Loss of consciousness 41.32 37.66 21 1028 18746 2338290
Palpitations 40.91 37.66 20 1029 16436 2340600
High density lipoprotein decreased 39.13 37.66 8 1041 355 2356681
Hyperhidrosis 39.10 37.66 19 1030 15403 2341633

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Flushing 2043.46 39.72 393 1125 5886 1739377
Pruritus 576.95 39.72 187 1331 23035 1722228
Product residue present 406.27 39.72 74 1444 712 1744551
Drug hypersensitivity 270.75 39.72 96 1422 15039 1730224
Skin burning sensation 188.83 39.72 39 1479 745 1744518
Erythema 183.25 39.72 71 1447 14117 1731146
Rash 172.42 39.72 92 1426 38601 1706662
Blood glucose increased 154.58 39.72 58 1460 10526 1734737
Feeling hot 150.63 39.72 42 1476 2945 1742318
Myalgia 149.13 39.72 63 1455 15595 1729668
Burning sensation 133.90 39.72 39 1479 3196 1742067
Paraesthesia 126.53 39.72 50 1468 10401 1734862
High density lipoprotein decreased 125.44 39.72 27 1491 631 1744632
Rhabdomyolysis 120.21 39.72 49 1469 11041 1734222
Blood creatine phosphokinase increased 95.43 39.72 39 1479 8817 1736446
Hot flush 93.72 39.72 28 1490 2497 1742766
Dizziness 87.18 39.72 57 1461 34304 1710959
Urticaria 77.14 39.72 37 1481 12204 1733059
Dyspnoea 61.96 39.72 55 1463 52004 1693259
Pain in extremity 60.18 39.72 36 1482 18436 1726827
Gout 55.63 39.72 19 1499 2597 1742666
Hypersensitivity 52.20 39.72 27 1491 10417 1734846
Blood triglycerides increased 51.85 39.72 18 1500 2582 1742681
Hepatotoxicity 48.85 39.72 18 1500 3066 1742197
Hepatic enzyme increased 47.75 39.72 22 1496 6599 1738664
Syncope 47.11 39.72 28 1490 14141 1731122
Asthenia 45.90 39.72 39 1479 34631 1710632
Nausea 43.53 39.72 45 1473 51151 1694112
Pain 41.56 39.72 33 1485 26624 1718639
Glycosylated haemoglobin increased 41.23 39.72 14 1504 1877 1743386

Pharmacologic Action:

SourceCodeDescription
ATC C04AC01 CARDIOVASCULAR SYSTEM
PERIPHERAL VASODILATORS
PERIPHERAL VASODILATORS
Nicotinic acid and derivatives
ATC C10AD02 CARDIOVASCULAR SYSTEM
LIPID MODIFYING AGENTS
LIPID MODIFYING AGENTS, PLAIN
Nicotinic acid and derivatives
ATC C10AD52 CARDIOVASCULAR SYSTEM
LIPID MODIFYING AGENTS
LIPID MODIFYING AGENTS, PLAIN
Nicotinic acid and derivatives
ATC C10BA01 CARDIOVASCULAR SYSTEM
LIPID MODIFYING AGENTS
LIPID MODIFYING AGENTS, COMBINATIONS
HMG CoA reductase inhibitors in combination with other lipid modifying agents
CHEBI has role CHEBI:75769 B vitamin
CHEBI has role CHEBI:35620 vasodilator agent
CHEBI has role CHEBI:50247 antidote
CHEBI has role CHEBI:35679 antilipemic drug
FDA EPC N0000175594 Nicotinic Acid
FDA Chemical/Ingredient N0000007641 Nicotinic Acids
MeSH PA D000963 Antimetabolites
MeSH PA D002317 Cardiovascular Agents
MeSH PA D000960 Hypolipidemic Agents
MeSH PA D057847 Lipid Regulating Agents
MeSH PA D018977 Micronutrients
MeSH PA D014665 Vasodilator Agents
MeSH PA D014803 Vitamin B Complex
MeSH PA D014815 Vitamins

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Hypercholesterolemia indication 13644009
Hyperlipidemia indication 55822004 DOID:1168
Vitamin deficiency indication 85670002
Familial hypercholesterolemia - heterozygous indication 238079002
Mixed hyperlipidemia indication 267434003
Hypertriglyceridemia indication 302870006

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 2.31 acidic
pKa2 4.85 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Hydroxycarboxylic acid receptor 2 GPCR AGONIST Ki 7.30 CHEMBL SCIENTIFIC LITERATURE
Nicotinate-nucleotide pyrophosphorylase [carboxylating] Enzyme WOMBAT-PK
Nicotinamide N-methyltransferase Enzyme WOMBAT-PK
Hydroxycarboxylic acid receptor 3 GPCR AGONIST EC50 6.52 IUPHAR
Nicotinamide phosphoribosyltransferase Enzyme WOMBAT-PK
Hydroxycarboxylic acid receptor 2 GPCR Ki 7.48 CHEMBL
Hydroxycarboxylic acid receptor 2 GPCR IC50 6.85 CHEMBL

External reference:

IDSource
4019440 VUID
N0000147570 NUI
C0027996 UMLSCUI
D00049 KEGG_DRUG
2679MF687A UNII
373 INN_ID
63639004 SNOMEDCT_US
4017661 VANDF
4019440 VANDF
7161 MMSL
273943001 SNOMEDCT_US
2275 MMSL
5169 MMSL
d00314 MMSL
7393 RXNORM
001052 NDDF
938 PUBCHEM_CID
CHEBI:15940 CHEBI
CHEMBL573 ChEMBL_ID
DB00627 DRUGBANK_ID
NIO PDB_CHEM_ID
D009525 MESH_DESCRIPTOR_UI
1588 IUPHAR_LIGAND_ID

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Niaspan HUMAN PRESCRIPTION DRUG LABEL 1 0074-3074 TABLET, FILM COATED, EXTENDED RELEASE 500 mg ORAL NDA 17 sections
Niaspan HUMAN PRESCRIPTION DRUG LABEL 1 0074-3079 TABLET, FILM COATED, EXTENDED RELEASE 750 mg ORAL NDA 17 sections
Niaspan HUMAN PRESCRIPTION DRUG LABEL 1 0074-3080 TABLET, FILM COATED, EXTENDED RELEASE 1000 mg ORAL NDA 17 sections
Niaspan HUMAN PRESCRIPTION DRUG LABEL 1 0074-3265 TABLET, FILM COATED, EXTENDED RELEASE 500 mg ORAL NDA 17 sections
Niaspan HUMAN PRESCRIPTION DRUG LABEL 1 0074-3274 TABLET, FILM COATED, EXTENDED RELEASE 750 mg ORAL NDA 17 sections
Niaspan HUMAN PRESCRIPTION DRUG LABEL 1 0074-3275 TABLET, FILM COATED, EXTENDED RELEASE 1000 mg ORAL NDA 17 sections
Niacor HUMAN PRESCRIPTION DRUG LABEL 1 0245-0067 TABLET 500 mg ORAL ANDA 12 sections
Vitafol HUMAN PRESCRIPTION DRUG LABEL 11 0642-0070 CAPSULE, GELATIN COATED 15 mg ORAL unapproved drug other 6 sections
Vitafol HUMAN PRESCRIPTION DRUG LABEL 9 0642-0072 CAPSULE 15 mg ORAL UNAPPROVED DRUG OTHER 9 sections
Vitafol-OB Plus DHA HUMAN PRESCRIPTION DRUG LABEL 10 0642-0076 KIT 18 mg None Unapproved drug other 13 sections
Select OB HUMAN PRESCRIPTION DRUG LABEL 11 0642-0077 TABLET, CHEWABLE 15 mg ORAL UNAPPROVED DRUG OTHER 11 sections
Vitafol OB HUMAN PRESCRIPTION DRUG LABEL 9 0642-0079 TABLET 18 mg ORAL Unapproved drug other 11 sections
Vitafol HUMAN PRESCRIPTION DRUG LABEL 12 0642-0092 CAPSULE, LIQUID FILLED 15 mg ORAL UNAPPROVED DRUG OTHER 10 sections
Vitafol Fe Plus HUMAN PRESCRIPTION DRUG LABEL 12 0642-0096 KIT 15 mg None UNAPPROVED DRUG OTHER 10 sections
Strovite Forte HUMAN PRESCRIPTION DRUG LABEL 11 0642-0204 TABLET, COATED 100 mg ORAL UNAPPROVED DRUG OTHER 11 sections
Reaphirm Plant Source DHA HUMAN PRESCRIPTION DRUG LABEL 11 0642-3010 CAPSULE, GELATIN COATED 15 mg ORAL unapproved drug other 6 sections
O-Cal Prenatal Vitamin HUMAN PRESCRIPTION DRUG LABEL 12 0813-0202 TABLET 17 mg ORAL UNAPPROVED DRUG OTHER 6 sections
Niacin HUMAN PRESCRIPTION DRUG LABEL 1 10135-612 TABLET, EXTENDED RELEASE 500 mg ORAL ANDA 18 sections
Niacin HUMAN PRESCRIPTION DRUG LABEL 1 10135-613 TABLET, EXTENDED RELEASE 750 mg ORAL ANDA 18 sections
Niacin HUMAN PRESCRIPTION DRUG LABEL 1 10135-614 TABLET, EXTENDED RELEASE 1000 mg ORAL ANDA 18 sections
TriStart DHA HUMAN PRESCRIPTION DRUG LABEL 15 15370-250 CAPSULE, LIQUID FILLED 5 mg ORAL UNAPPROVED DRUG OTHER 11 sections
Niaspan HUMAN PRESCRIPTION DRUG LABEL 1 21695-852 TABLET, FILM COATED, EXTENDED RELEASE 500 mg ORAL NDA 17 sections
Niaspan HUMAN PRESCRIPTION DRUG LABEL 1 21695-865 TABLET, FILM COATED, EXTENDED RELEASE 1000 mg ORAL NDA 17 sections
Prenatal Vitamins Plus Low Iron HUMAN PRESCRIPTION DRUG LABEL 13 39328-106 TABLET 20 mg ORAL Unapproved drug other 8 sections
NIACIN HUMAN PRESCRIPTION DRUG LABEL 1 47335-539 TABLET, FILM COATED, EXTENDED RELEASE 500 mg ORAL ANDA 18 sections
NIACIN HUMAN PRESCRIPTION DRUG LABEL 1 47335-613 TABLET, FILM COATED, EXTENDED RELEASE 1000 mg ORAL ANDA 18 sections
NIACIN HUMAN PRESCRIPTION DRUG LABEL 1 47335-614 TABLET, FILM COATED, EXTENDED RELEASE 750 mg ORAL ANDA 18 sections
Multivitamin with fluoride HUMAN PRESCRIPTION DRUG LABEL 10 50090-0356 TABLET, CHEWABLE 13.50 mg ORAL UNAPPROVED DRUG OTHER 8 sections
Multivitamin with fluoride HUMAN PRESCRIPTION DRUG LABEL 10 50090-0435 TABLET, CHEWABLE 13.50 mg ORAL UNAPPROVED DRUG OTHER 8 sections
Niacin HUMAN PRESCRIPTION DRUG LABEL 1 50268-584 TABLET, EXTENDED RELEASE 500 mg ORAL ANDA 18 sections